Effect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C

Overview of attention for article published in PLOS Medicine, January 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

news: 1 news outlet
twitter: 49 X users

reddit: 1 Redditor
bluesky: 4 Bluesky users

Readers on

mendeley: 13 Mendeley

So far, Altmetric has seen 4 Bluesky posts from 4 Bluesky users, with an upper bound of 10,616 followers.

Congratulations to CHIP PhD student, Abhishek Bhatia, for publishing a first author article in PLOS Medicine! We are so proud of you Abhi!! 🎉 Read more here: journals.plos.org/plosmedicine...

RP @atranscendedman.bsky.social: A study of 703,647 U.S. patients found Paxlovid reduced COVID-19 hospitalizations by 39% overall and deaths by 61%. It cut hospitalizations by 33% in ages 18-49, 44% in 50-64, and 41% in 65+, with the greatest absolute…

A study of 703,647 U.S. patients found Paxlovid reduced COVID-19 hospitalizations by 39% overall and deaths by 61%. It cut hospitalizations by 33% in ages 18-49, 44% in 50-64, and 41% in 65+, with the greatest absolute risk reduction in older adults. …

Effect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19 ->PLOS ONE | #Covid19 | More info from EcoSearch

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.